학술논문
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Document Type
Artikel
Author
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, AC; Arnedos, M; Balmana, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, SM; Eisen, A; Elsafy, F; Fein, LE; Fielding, A; Ford, JM; Friedman, S; Gelmon, KA; Gianni, L; Gnant, M; Hollingsworth, SJ; Im, SA; Jager, A; Lakhani, SR; Janni, W; Linderholm, B; Liu, TW; Loman, N; Korde, L; Loibl, S; Lucas, PC; Marme, F; de Duenas, EM; McConnell, R; Phillips, KA; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, CF; Spanic, T; Stickeler, E; Toi, M; Traina, TA; Viale, G; Zoppoli, G; Park, YH; Yerushalmi, R; Yang, H; Pang, D; Jung, KH; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, GS; Sun, Q; Parton, M; Colleoni, MA; Schmidt, M; Brufsky, AM; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, ANJ; Johannsson, OT
Source
Annals of oncology : official journal of the European Society for Medical Oncology. 33(12):1250-1268
Subject
Language
English
English
English
ISSN
1569-8041